CastleArk Alternatives’s Halozyme HALO Stock Holding History

CastleArk Alternatives’s Portfolio HALO Stock Details HALO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-219,787	Closed	-$8.94M	–	130
2021 Q3	$8.94M	Buy	+219,787	New	+$9.19M	0.34%	82

Other funds holding HALO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

SCM

Snyder Capital Management San Francisco, California $5.16B AUM 26.72% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

CastleArk Alternatives's HALO Position: Q4 2021 in Review

CastleArk Alternatives sold out of Halozyme (HALO) in Q4 2021, closing a stake of 219,787 shares — an estimated $8.94M sold.

CastleArk Alternatives first reported a position in HALO in Q3 2021 and held it in 1 quarter. The position peaked at $8.94M in Q3 2021. 324 funds tracked by Wall St. Rank hold HALO as of Q4 2021.

CastleArk Alternatives reported no remaining Halozyme position as of Q4 2021 after selling out during the quarter.
CastleArk Alternatives sold 219,787 Halozyme shares in Q4 2021, an estimated $8.94M.
CastleArk Alternatives first reported a position in Halozyme in Q3 2021 and held it in 1 quarter.
CastleArk Alternatives's Halozyme position peaked at $8.94M in Q3 2021.
324 funds tracked by Wall St. Rank held Halozyme as of Q4 2021.

Based on CastleArk Alternatives's 13F filing for Q4 2021, filed 18 Feb 2022.